AstraZeneca has boosted its presence in the race to develop a vaccine for respiratory syncytial virus (RSV), via a $1.1bn deal with American company Icosavax. The agreement means AstraZeneca, which is also the co-developer of the RSV-specific antibody Beyfortus, will gain access to Icosavax’s RSV vaccine candidate. The U.K. multinational’s move comes after GSK’s Arexvy became the first-ever RSV vaccine to go to market, approved by the FDA, followed shortly by Pfizer’s own vaccine.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
